California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
25 juil. 2024 21h36 HE
|
Nexcella, Inc.
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
18 avr. 2024 09h37 HE
|
Nexcella, Inc.
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites...
Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
04 janv. 2024 09h47 HE
|
Nexcella, Inc.
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific...
Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
18 déc. 2023 09h47 HE
|
Nexcella, Inc.
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized...
Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
11 déc. 2023 09h46 HE
|
Nexcella, Inc.
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior...
Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
21 nov. 2023 09h56 HE
|
Nexcella, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for...
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
06 nov. 2023 09h18 HE
|
Nexcella, Inc.
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10,...
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
06 nov. 2023 08h46 HE
|
Nexcella, Inc.
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy98% overall response rate observed in relapsed/refractory...
Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
26 oct. 2023 09h03 HE
|
Nexcella, Inc.
Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in...
Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
16 oct. 2023 09h10 HE
|
Nexcella, Inc.
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy...